Published in J Immunol on July 15, 2000
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 2.82
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 1.65
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother (2008) 1.32
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci (2006) 1.31
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun (2007) 1.28
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood (2007) 1.26
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 1.01
The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med (2002) 0.96
Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol (2010) 0.96
Identification of HLA-Cw6.02 and HLA-Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries. Immunogenetics (2004) 0.94
Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor. J Immunol (2010) 0.90
Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol (2010) 0.90
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant (2015) 0.89
Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother (2012) 0.88
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother (2012) 0.88
Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions. Immunology (2010) 0.86
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
Superagonism at G protein-coupled receptors and beyond. Br J Pharmacol (2015) 0.84
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol (2010) 0.84
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood (2006) 0.83
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol (2010) 0.81
Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules. Protein Sci (2005) 0.81
Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc Natl Acad Sci U S A (2016) 0.80
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother (2008) 0.79
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology (2016) 0.78
An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Front Immunol (2013) 0.78
Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination. J Biol Chem (2016) 0.77
Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology (2017) 0.75
Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife (2016) 0.75
Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes. PLoS One (2013) 0.75
Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. Cancer Res (2016) 0.75
CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization. Cells (2013) 0.75
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncoimmunology (2017) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Tumor necrosis factor (TNF). Science (1985) 8.80
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature (1990) 6.41
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J Cell Biol (1998) 5.03
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Improved complementation in the cytotoxic test. Transplantation (1970) 3.93
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. J Biol Chem (1974) 3.80
Assembly of MHC class I molecules analyzed in vitro. Cell (1990) 3.77
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Glycogen storage disease in adults. Ann Intern Med (1994) 3.58
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Ly-C: a third locus specifying alloantigens expressed only on thymocytes and lymphocytes. Transplantation (1971) 3.42
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
New paths in human cancer serology. J Exp Med (1998) 3.12
Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.06
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest (1999) 3.00
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79